NYHA-ICD Benefit Index Calculator
Clinical risk-factor assessment
Use the definitions and thresholds shown below. All fields are required.
Complete all fields
The score and study context will appear when all values are valid.
The source study involved patients with prior myocardial infarction and ischemic left ventricular dysfunction in MADIT-II. Applicability to other populations is not established by this calculator.
About the risk score
Goldenberg and colleagues developed a simple count of five clinical risk factors to stratify all-cause mortality and explore variation in observed ICD survival benefit among patients with ischemic left ventricular dysfunction enrolled in MADIT-II. The model is not the same as the four-variable score in the original uploaded file.
Risk markers and thresholds
| Variable | Risk marker | Points |
|---|---|---|
| NYHA functional class | Greater than II (III–IV) | 1 |
| Age | Greater than 70 years | 1 |
| BUN | Greater than 26 and less than 50 mg/dL | 1 |
| QRS duration | Greater than 120 ms | 1 |
| Atrial fibrillation | Present at baseline | 1 |
How to interpret the result
Zero risk factors: the original analysis did not identify a survival benefit from ICD therapy in this subgroup. One or more risk factors: ICD therapy was associated with a 49% relative reduction in risk of death in the study population. Patients with BUN ≥50 mg/dL and/or creatinine ≥2.5 mg/dL were analyzed separately as a very-high-risk group, in whom benefit was not identified.
These findings are study-specific subgroup results, not a direct estimate of an individual patient's absolute benefit. Do not interpret a higher score as automatically meaning greater ICD benefit; the study described a non-linear pattern of treatment effect.
Reference
The published model selected NYHA class greater than II, atrial fibrillation, QRS duration greater than 120 ms, age greater than 70 years, and BUN greater than 26 mg/dL (with the very-high-risk renal dysfunction group excluded from the primary risk-score analysis).
Scope and limitations
- Derived from a specific post-myocardial-infarction, ischemic LV dysfunction trial population.
- Not validated here for nonischemic cardiomyopathy or secondary-prevention ICD decisions.
- Does not replace current guidelines, clinical assessment, or discussion of competing non-arrhythmic mortality and patient preferences.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.